Print Magazine
Brussels Morning Newspaper
Wednesday, May 18, 2022
No Result
View All Result
  • Home
    • About Us
  • EU institutions
    • Commission
    • Parliament
    • Council
  • Europe
  • World
  • Economy
  • Culture and Society
  • In Depth
    • Ambassador’s Corner
    • The American Angle
    • Europe With Transparency
    • Sustainable Perspective
    • Place de la Bourse
    • The Macro-Economist
    • Southeast Europe
Brussels Morning Newspaper
  • Home
    • About Us
  • EU institutions
    • Commission
    • Parliament
    • Council
  • Europe
  • World
  • Economy
  • Culture and Society
  • In Depth
    • Ambassador’s Corner
    • The American Angle
    • Europe With Transparency
    • Sustainable Perspective
    • Place de la Bourse
    • The Macro-Economist
    • Southeast Europe
Brussels Morning Newspaper
No Result
View All Result
Home Culture and Society

COVID-19 vaccines to be approved in 2020 by EMA

Marta Pacheco by Marta Pacheco
26 January 2021
in Culture and Society
COVID-19 vaccines to be approved in 2020 by EMA
Share on FacebookShare on Twitter

Brussels (Brussels Morning) Marketing approval for COVID-19 vaccines in the EU will be granted by 29 December for Pfizer and BioNTech, and 1 January for Moderna. 

The announcement was made by the executive director of the European Medicines Agency’s (EMA) Emer Cooke, following a European Parliament hearing on COVID-19 vaccines, led by MEP Pascal Canfin MEP (Liste Renaissance).

The medicine agency held a public meeting today to “listen to concerns and questions from the public”, Cooke said, while “aspects of EMA’s scientific evaluation” were detailed by EMA’s Marco Cavaleri, Fergus Sweeney and Peter Arlett. 

The online event provided a platform for patients’ representatives, consumers, industry, healthcare professionals and academia to voice their views on the rush for a vaccine to deal with the pandemic.

It came two days after the EMA suffered a cyber attack involving incognito access to the regulatory submission for the Pfizer and BioNTech’s COVID-19 vaccine candidate, which Cooke made reference to while addressing MEPs yesterday and the wider public today.

Market Authorisation

Cooke presented an overview of the status of the vaccines in the EU, alluding particularly to its market authorisation, which would allow vaccine distribution to the general public by the end of the year or early next year. However, last-minute changes may arise, she warned.

A total of four vaccines are under review, including those developed by AstraZeneca and Oxford University, and Janssen. 

The EMA said that issues related to post-authorisation of the inoculations required strong collaboration between the agency, the European Centre for Disease Prevention and Control (ECDC) and national authorities.

Cooke said she wanted to “assure” the public that EMA’s scientific assessment “will be fully independent” based on the “strength of the scientific evidence of vaccines’ safety, quality and efficacy”. 

“Authorisation will only be granted when the evidence convincingly shows that the benefits are greater than the risks of the vaccine”, added Cooke.

Transparency

During her presentation, EMA’s executive director reinforced the need for transparency when dealing with placement in the market of any COVID-19 vaccine. 

Cooke said that “effective communication” was necessary to gain the trust of the public and said the agency would publish “the [vaccine’s] assessment report within three days of the Commission’s decision”.

According to her statement, all clinical trial results assessed by EMA will be available on its website. As an exception to the rule, she said, the vaccines’ risk management plans will also be published. 

“We don’t just want to publish information, but to communicate better”, said Melanie Carr, head of EMA’s stakeholders and communication.

Side effects

However, Cooke said an approved vaccine would not be a “silver bullet” and advocated for social distancing measures to continue. “We know a lot more than we did six months ago, but we still have a lot to learn”, she cautioned.

When addressing EMA’s chief, MEP Margarita de la Pisa (ECR), raised concerns saying that “we don’t have time to know the long-term side effects” of the vaccines. 

She further added that messenger RNA vaccines (mRNA) — such as that produced by Pfizer and BioNTech — may help “develop self-immune diseases”. 

De la Pisa, a pharmacist by training, claimed that those more in need, including the immune-compromised, maybe the cluster suffering more from side effects and called on extra safety measures when dealing with these specific cases.

Patient and consumer representatives have also raised concerns over side effects during EMA’s public meeting today. 

Rollout

On 8 December, the COVID-19 vaccine commenced rollout in the UK, despite disapproval from the European Parliament for not following EMA’s authorisation. 

The UK government has explained the process that they believed justified the approval of the Pfizer and BioNTech vaccine. 

Bahrain and Canada also started administering the vaccine shortly afterward. The EU will be the fourth market to have access to the jabs, which is expected to allow citizens to slowly return to a “normal” life. 

We are starting the public meeting on #COVID19vaccines.
Join us to learn more of the EU scientific evaluation for #COVID19vaccines and to hear the voice of people on this subject: https://t.co/G5euT56KO3#EMAPublicMeeting

— EU Medicines Agency (@EMA_News) December 11, 2020
Tags: Brussels LatestCovid-19European Medicines Agency (EMA)Main-Slidervaccines

Latest post

The Brexit Final Act

Britain prepares law to override parts of Brexit treaty

9 hours ago
Berlin

What Are 10 Best Hotels In Berlin?

10 hours ago

Most Read

  • shutterstock_1821616664

    MEPs send Open Letter urging the Home Secretary Priti Patel to reject Assange’s extradition

    0 shares
    Share 0 Tweet 0
  • These are the 10 highest paying jobs in the Europe in 2022

    0 shares
    Share 0 Tweet 0
  • Why corruption matters

    0 shares
    Share 0 Tweet 0
  • Brussels residents want to set up school for Ukrainian children

    0 shares
    Share 0 Tweet 0
  • Government approves route for ‘Mediatram’ from Meiser

    0 shares
    Share 0 Tweet 0
Facebook Twitter Youtube LinkedIn

About Us

Brussels Morning is a daily online newspaper based in Belgium. BM publishes unique and independent coverage on international and European affairs. With a Europe-wide perspective, BM covers policies and politics of the EU, significant Member State developments, and looks at the international agenda with a European perspective.

Category

  • Ambassador’s Corner
  • Belgium News
  • Brussels
  • Commission
  • Council
  • Culture and Society
  • Diplomacy
  • Economy
  • EU Institutions
  • Europe
  • Europe With Transparency
  • Features
  • In Depth
  • Member States
  • Middle East Eye
  • Opinion
  • Our pick
  • Parliament
  • Place de la Bourse
  • Southeast Europe
  • Sustainable Perspective
  • The American Angle
  • The Macro-Economist
  • Uncategorised
  • US Elections
  • World

More info

  • About Us
  • Advertising
  • Cookies Policy
  • Contact Us
  • FAQ
  • Jobs

Brussels Morning Newspaper - All Rights Reserved © 2020

No Result
View All Result
  • Home
  • About Us
  • EU Institutions
    • Parliament
    • Commission
    • Council
  • Europe
  • World
  • Member States
  • Economy
  • Culture and Society
  • In Depth
    • Ambassador’s Corner
    • Europe With Transparency
    • Place de la Bourse
    • The Macro-Economist
    • Sustainable Perspective
    • The American Angle
    • Southeast Europe
  • Print Magazine

Brussels Morning Newspaper - All Rights Reserved © 2020

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Cookie settingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT